For precision genetic medicines to fulfill their potential as treatments for ultra-rare diseases, fresh approaches to academic–industry partnerships and data sharing are needed, together with regulatory change and adaptation of reimbursement models.
- Julia M. Y. Pian
- Nana Owusu
- Timothy W. Yu